Hear ye hear ye!! New pembrolizumab TMB tumor-agnostic threshold is 13 rather than 10. 🔥 Our data suggests it is 16 mut/mb (best threshold) Data coming soon! Responses can be phenomenal. I have patients who went from “next step hospice” to “CR ongoing for years— aka cured”

Driving in Detroit is fun until you realize you needed to be in a different lane three miles ago and now you’re entering Canada

Lymph node-targeted, mKRAS-specific amphiphile vaccine in #PancreaticCancer: the randomized phase 2 AMPLIFY-7P trial (@ElicioTx) nature.com/articles/s41591-0… Most important panel: in post surgical setting ctDNA positivity is pivotal driver of disease free survival, agnostic to vaccine

#ESMO26 🚀 RASolute 302 | Phase III 👥 500 pts | Previously treated mPDAC 💊 Daraxonrasib (RAS(ON) inhibitor) vs chemo 📈 OS: 13.2 vs 6.7 mo (HR 0.40) 🧬 OS benefit by RAS genotype: 🔹 G12D: HR 0.49 🔹 G12V: HR 0.32 🔹 G12R: HR 0.61 📊 PFS: HR 0.55 (BICR) 🎯 ORR: 32% vs 11% 💡 new SOC! @OncoAlert

It’s been a long road from studying some of the first neoantigens in the modern immunotherapy era. Neoantigens are actionable in a phase 3 study! Moderna mRNA vaccine almost halves the risk of skin cancer returning nature.com/articles/d41586-0…

Amazing. 🎯🔥We published this in 2023. 2.5 years later, May 2026, Japan gives world-first tumor-agnostic approval to alectinib for ALK fusion solid cancers

Just the Editor-in-Chief of Nature advising scientists not to share their data and findings with external AI model companies.

Everyone knows the mitochondria is the "powerhouse of the cell." But have you seen how beautifully its movement was captured by Dr. Patrick C. Hickey in this 5th place #SmallWorldInMotion winning video? 🏆 Now you have! bit.ly/3TgEWKn

Check out the newly organized website of Cancer Sciences, the home of enterprise basic and translational oncology research at the Cleveland Clinic lerner.ccf.org/cancer-scienc…

⚡️Randomized phase III trial of adjuvant RT vs observation after gross total resection of WHO grade 2 meningioma just got published ⚡️ 157 pts ➡️ 78 RT ➡️ 79 observation ➡️ RT = 60 Gy/30 fx ➡️ median follow-up ~5 years At ~5 years: 🔁 Recurrence: 14% with RT vs 30% with obs 📈 5-year DFS: 80% vs 64% ❗️There was no difference in OS, but only 13 pts died in the entire trial, and 95% CI was huge 0.27-3.05. So one really can't tell from this study whether RT improves, worsens, or has no effect on OS. It was simply far too underpowered for that endpoint. Could salvage tx in the obs arm attenuate OS difference? Possibly. More pts in the obs arm required 2nd-line tx (20% vs 10% with RT), but ROAM doesn't quite establish that salvage tx explains the lack of OS difference - it is a plausible interpretation, but not a proven conclusion. ✔️QoL and neurocognitive outcomes were similar which is reassuring, but QoL data were available in only 38% of pts at 5 yrs, while by 2 yrs ~45% of neurocognitive data were missing. So there is simply too much missing data to conclude that either strategy leads to better or worse QoL or neurocognitive function. After all, if a tumor recurs and a pt needs salvage surgery and/or RT, it is plausible that QoL could worsen simply from the burden of additional tx 🎯 My take-home: RT reduces the risk of recurrence after GTR of grade 2 meningioma But, just like in breast, prostate, and other cancers with otherwise favorable prognosis, there will be a sizable group of pts who would never recur even without additional tx. Here, about 70% of pts observed had not recurred at ~5 years. So, as with most things in oncology, selection is really the 🔑 I’d particularly consider RT in younger patients and those with higher-risk clinical and/or molecular features and in cases where postop 68Ga-DOTATATE PET detects residual disease that may not be clearly visible on MRI.

Well, being delayed at La Guardia isn’t so bad now. If we had the new LGA when I was living in NY, quality of life would have been measurably higher

In 1980, 21% of NIH-funded principal investigators were under age 35. By 2015, this proportion was 3%. The dramatic ageing of independent scientists is bad because old people are simply worse at science than young people. Latest meta-scientific deep-dive from me 🧵 ⬇️

Every Midwesterner this week

Excited to share our new paper, out today in @ScienceMagazine! We developed senescence-modulating nanoparticles (SMNPs) that target P-selectin+ pathogenic senescent-like macrophages in fibrotic tissues and tumors. science.org/doi/10.1126/scie…

Lighting up your screen: a larval zebrafish's cellular activity. Developed by researchers at our Janelia Research Campus, WHaloCaMP is a biosensor that detects calcium signals & offers a window into how cells & organs work together. 🎥 Helen Farrants, HHMI JRC

VeloSano is truly inspirational. Community support makes breakthroughs in cancer possible. I am grateful to everyone who rode, cheered, and donated. #Research @CleClinicMD #cancerresearch #VeloSano

if institutional status becomes moral currency, physicians can feel pressure to accept conditions they would otherwise question. Gratitude is subtly framed as professionalism, and professionalism becomes equated with quiet acceptance. opmed.doximity.com/articles/…

Great to see neoantigen based therapies show benefit in a phase 3 trial. It’s been a long road!

Get rid of the term provider and “caregiver “

Get rid of the term "provider" in health care! The need and steps for action. @AnnalsofIM acpjournals.org/doi/10.7326/…